| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/1b interim results example | Phase 1/1b | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 1/1b interim results example | Phase 1/1b | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 1/1b interim results example | Phase 1/1b | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Pasithea Therapeutics Corp.$0.49
0 (-0.49%)
D 30Pipeline Score Fair Value Pharma · Clinical
Market Cap
23.38 M
EPS
-2.07
P/E Ratio
-
Value Trade
233.87 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.94 M
Operating CF
-4.79 M
Total Assets
56.35 M
Total Liabilities
1.54 M
Equity
54.81 M
D/E Ratio
12,345
-12.53 %
Week
0.98 %
1 Month
-12.53 %
3 Month
95.37 %
6 Month
-99.13 %
5 Year
-99.13 %
All Time
Cash Data
Cash Position
50.40 M
Monthly Burn
1.60 M
Runway
29.7 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
403.02 K
52 Week Range
0.28 - 2.06
% held by Insiders
8.48 %
% held by Institutions
56.26 %
Enterprise Value
-27.12 M
Total Shares
24.95 M
Short %
0.94 %
Float Shares
20.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pasithea Therapeutics Corp.
162Total events
4Upcoming
22Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 2
TBD
T2Oral Presentation
Subscribe to view catalyst details
TBD
T1Interim Analysis
Subscribe to view catalyst details
Event history 2
TBD
▲Interim AnalysisPAS-004Trial
Subscribe to view catalyst details
TBD
●Protocol AmendmentPAS-004Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-11-10 | PAS-004 (next-generation macrocyclic MEK inhibitor) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-11-10 | PAS-004 (next-generation macrocyclic MEK inhibitor) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-11-10 | PAS-004 (next-generation macrocyclic MEK inhibitor) | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D30
Pipeline Score $19M
Pipeline ValueFair Value
Valuation Signal1
Drugs Scored0.8x
rNPV / MCap Top 35%
Micro Cap (rank 594 of 912)
Percentile RankPasithea Therapeutics Corp. faces pipeline headwinds (30/100), with $76M risk-adjusted pipeline value, led by PAS-004 in NF1 Mutation (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAS-004 Small molecule | NF1 Mutation | Phase 1 | NCT06961565 | 34% | $76M | RECRUITING | 56 | STALLED | D (36) | Dec 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PAS-004 Fast TrackOrphanRare Pediatric | advanced cancer | Phase 1 | 2026-06-30 | 34 patients have been enrolled and dosed; No dose-limiting toxicities (DLTs), and no discontinuations due to TRAEs; 10 patients on study for >90 days, of which 6 patients >150 days, 4 patients >300 days, and 2 patients >365 days; All TRAEs were Grade 1 or Grade 2; Low cumulative rates of rash (12%) and diarrhea (6%) Read More | Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Read More | |
PAS-004 Fast TrackOrphanRare Pediatric | advanced cancer | Phase 1 | 2026-06-30 | 34 patients have been enrolled and dosed; No dose-limiting toxicities (DLTs), and no discontinuations due to TRAEs; 10 patients on study for >90 days, of which 6 patients >150 days, 4 patients >300 days, and 2 patients >365 days; All TRAEs were Grade 1 or Grade 2; Low cumulative rates of rash (12%) and diarrhea (6%) Read More | Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Read More | |
PAS-004 Fast TrackOrphanRare Pediatric | advanced cancer | Phase 1 | 2026-06-30 | 34 patients have been enrolled and dosed; No dose-limiting toxicities (DLTs), and no discontinuations due to TRAEs; 10 patients on study for >90 days, of which 6 patients >150 days, 4 patients >300 days, and 2 patients >365 days; All TRAEs were Grade 1 or Grade 2; Low cumulative rates of rash (12%) and diarrhea (6%) Read More | Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KTTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KTTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KTTAPasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Pasithea Therapeutics Corp. announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026. The summit will focus on various neurological and psychiatric disorders, featuring investor meetings and discussions. Pasithea's management will be available for one-on-one meetings, highlighting their ongoing clinical trials for PAS-004, a macrocyclic MEK inhibitor.
Read more →KTTAPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Pasithea Therapeutics has reported positive interim data from its Phase 1 trial of PAS-004, a MEK inhibitor for advanced cancer patients. The drug demonstrated a favorable safety profile, with all treatment-related adverse events classified as Grade 1 or 2. Notably, some patients exhibited stable disease for over six months, surpassing typical progression-free survival rates for similar treatments. The company plans to expand dose escalation and assess food effects on drug pharmacokinetics.
Read more →KTTA▼ -8.9%on this news
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics has amended its Phase 1/1b clinical trial protocol for PAS-004 in NF1 patients. The updates include additional dose levels and an extended treatment period, allowing for more comprehensive data collection. The company has successfully enrolled additional patients and aims to provide interim data in Q4 2026.
Read more →KTTA▼ -5.3%on this news· ran to -15% by day 3shared move
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
Pasithea Therapeutics will exhibit at the Children's Tumor Foundation 2026 NF Conference in Denver, Colorado, from June 26-30, 2026. The company aims to engage with the NF1 community following recent FDA designations for its lead treatment candidate, PAS-004. CEO Dr. Tiago Reis Marques emphasized the importance of collaboration to enhance outcomes for NF1 patients.
Read more →KTTA▼ -9.8%on this news
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea Therapeutics announced that the FDA has granted Orphan Drug Designation to its drug PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS). This designation is significant due to the limited treatment options available for ALS, a disease with a high unmet medical need. The company is also conducting clinical trials to explore PAS-004's efficacy and safety.
Read more →KTTAPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics has appointed Dr. Kartik Krishnan as Chief Medical Officer, effective May 1, 2026. Dr. Krishnan will lead clinical development for PAS-004, a MEK inhibitor targeting neurofibromatosis type 1. His extensive experience in advancing therapies is expected to enhance the company's efforts in this area.
Read more →KTTAPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics has received Rare Pediatric Disease Designation from the FDA for PAS-004, a treatment for Neurofibromatosis type 1 (NF1). This designation is significant as NF1 affects approximately 115,000 individuals in the U.S. The company is also conducting Phase 1/1b trials for PAS-004 in patients with NF1-associated plexiform neurofibromas.
Read more →KTTAPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics Corp. has received Fast Track designation from the FDA for its drug PAS-004, aimed at treating neurofibromatosis type 1 (NF1) associated plexiform neurofibromas. This designation allows for early and frequent communications with the FDA, facilitating product development. The company is currently engaged in Phase 1/1b clinical trials for this treatment, which addresses the serious health risks posed by plexiform neurofibromas in NF1 patients. The Fast Track status may allow for quicker regulatory approval processes if relevant criteria are met.
Read more →KTTAPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pasithea Therapeutics Corp. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Tiago Reis Marques will discuss the company's lead drug candidate, PAS-004, which is currently in clinical trials for treating NF1-associated plexiform neurofibromas. The presentation will be available via webcast, and management will hold one-on-one meetings with investors.
Read more →KTTAPasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Pasithea Therapeutics has provided an update on its PAS-004 clinical programs, highlighting positive early results from its Phase 1 trial in advanced cancer patients and ongoing trials for neurofibromatosis type 1. The company raised $60 million to support these initiatives, aiming to address significant unmet medical needs. However, they acknowledge the inherent risks in clinical trial outcomes and regulatory approvals.
Read more →KTTAPasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Pasithea Therapeutics has successfully closed a public offering of 80 million shares, raising approximately $60 million. The offering was led by notable healthcare investors and aims to support the company's ongoing clinical trials and research initiatives. The funds will enhance the company's cash runway, expected to last until at least mid-2028.
Read more →KTTA▲ +38.7%on this newsshared move
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Pasithea Therapeutics Corp. has announced the pricing of a public offering of 80 million shares at $0.75 each, aiming to raise approximately $60 million. The offering is set to close around December 1, 2025, and will support the company's ongoing research and development efforts, particularly for its lead drug candidate, PAS-004. The offering is facilitated by H.C. Wainwright & Co. and is backed by several healthcare-focused investors.
Read more →KTTA▲ +14.8%on this news· ran to +173% by day 3shared move
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
Pasithea Therapeutics Corp. has announced that it has been awarded a $1 million grant from the ALS Association to conduct a clinical trial for its drug PAS-004 in amyotrophic lateral sclerosis (ALS) patients. The trial will assess the safety, tolerability, and efficacy of PAS-004, a next-generation macrocyclic MEK inhibitor, which has previously shown promising results in animal models. This funding will facilitate the initiation of the first human clinical trial for PAS-004 aimed specifically at ALS, marking a significant milestone for the company.
Read more →KTTA▲ +45.3%on this news· ran to +403% by day 3shared move
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
Pasithea Therapeutics has completed Cohort 7 of its Phase 1 trial for PAS-004, a MEK inhibitor for advanced cancer patients. The trial reported no treatment-related adverse events and demonstrated a favorable pharmacokinetic profile. The safety review committee has recommended escalating to Cohort 8, indicating positive momentum for the drug's development.
Read more →KTTA▼ -12.3%on this news· ran to +218% by day 3shared move
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Pasithea Therapeutics announced positive pharmacokinetic data for its PAS-004 tablet formulation in an ongoing Phase 1/1b trial for adult patients with neurofibromatosis type 1. The tablet showed approximately threefold higher exposure compared to the capsule formulation, allowing for lower dosing with improved predictability. The trial continues to evaluate the safety and efficacy of PAS-004.
Read more →KTTA▼ -12.8%on this news· ran to -39% by day 1shared move
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study -- Evidence of Monotherapy A
Pasithea Therapeutics has announced positive interim Phase 1 data for its oral MEK inhibitor, PAS-004, used in advanced cancer patients. The trial demonstrated partial response and stable disease in patients with BRAF V600E mutations, achieving a 71.4% disease control rate. Additionally, PAS-004 exhibited a favorable safety profile with mostly mild treatment-related adverse effects. These encouraging results suggest potential for PAS-004 as a leading treatment option for neurofibromatosis type 1-related tumors.
Read more →KTTA▼ -5.9%on this news
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Pasithea Therapeutics has activated a new clinical trial site at the University of Alabama at Birmingham for its Phase 1/1b study of PAS-004 in adult patients with neurofibromatosis type 1. The trial aims to evaluate the safety and efficacy of PAS-004 in treating symptomatic plexiform neurofibromas. Enrollment at the UAB site is expected to begin immediately, enhancing the company's commitment to advancing care for NF1 patients.
Read more →KTTAPasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients -- First patient in South Korea dosed -- MIAMI, FL.
Pasithea Therapeutics Corp. has announced the activation of two clinical trial sites in South Korea for its Phase 1/1b study of PAS-004, a novel MEK inhibitor, aimed at treating adult patients with neurofibromatosis type 1 (NF1). The first patient has already been dosed at these sites, ASAN Medical Centre and Severance Hospital. The trial aims to evaluate the drug's safety, tolerability, and efficacy in this patient population. With approximately 10,000 NF1 patients in South Korea, the trial is positioned to enhance understanding and treatment options for those affected by this condition.
Read more →KTTAPasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Pasithea Therapeutics announced that its Phase 1/1b clinical trial for PAS-004 in adult NF1 patients has progressed to Cohort 2 after a positive review by the Safety Review Committee. The recommendation followed the review of safety data from the first cohort, which showed no dose limiting toxicities. The company has already enrolled the first three patients in the new cohort and expects initial interim clinical data in Q1 2026.
Read more →KTTAPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Pasithea Therapeutics Corp. has announced a change in the timing of its presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on September 8, 2025, at 5:00 PM ET. CEO Dr. Tiago Reis Marques will present the company’s developments, including updates on their lead drug candidate, PAS-004.
Read more →KTTA▲ +11.8%on this newsshared move
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Pasithea Therapeutics Corp. (NASDAQ: KTTA) will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, in New York City. CEO Dr. Tiago Reis Marques will lead a presentation and participate in one-on-one meetings with investors. The company is focused on its lead drug candidate, PAS-004, which is currently in Phase 1 clinical trials for advanced cancer and neurofibromatosis type 1-associated plexiform neurofibromas. However, the company acknowledges the potential risks and uncertainties associated with its forward-looking statements about trial outcomes and market opportunities.
Read more →KTTAPasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Pasithea Therapeutics has successfully completed enrollment and initial dosing of the first cohort in its Phase 1/1b clinical trial for PAS-004, a MEK inhibitor targeting neurofibromatosis type 1 (NF1). The trial evaluates the safety and tolerability of PAS-004 in adult patients with symptomatic and inoperable plexiform neurofibromas. The study also aims to identify recommended doses and assess preliminary efficacy on tumor volume and patient quality of life. Initial encouraging results from previous trials may enhance patient compliance, as PAS-004 is dosed once daily compared to existing therapies requiring more frequent dosing. Results from this trial are expected to contribute significantly to treatment options for NF1 patients.
Read more →KTTAPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Pasithea Therapeutics has appointed Dr. James Lee to its scientific advisory board to guide the development of PAS-004, a macrocyclic MEK inhibitor targeting ETS2 pathway inflammatory diseases. Dr. Lee's expertise in inflammatory bowel disease and his research on ETS2's role in inflammation are expected to significantly contribute to the drug's development. The company aims to expand PAS-004's applications beyond its current focus.
Read more →KTTAPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
Pasithea Therapeutics presented updated interim data from its Phase 1 study of PAS-004 at ASCO 2025. The study showed that PAS-004, a macrocyclic MEK inhibitor, demonstrated preliminary clinical activity in patients with heavily pre-treated solid tumors. Notably, patients experienced stable disease and tumor volume reduction, with no serious adverse events reported. The ongoing trial aims to evaluate the drug's safety, tolerability, and efficacy.
Read more →KTTAPasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
Pasithea Therapeutics has announced promising preclinical data for PAS-004, a MEK inhibitor, demonstrating its superior ability to inhibit ETS2 signaling linked to inflammation in diseases like inflammatory bowel disease (IBD). The study, conducted at the Francis Crick Institute, showed PAS-004 outperformed the FDA-approved selumetinib in a human macrophage model. The findings suggest PAS-004 could be a new treatment option for various inflammatory conditions.
Read more →KTTA▲ +11.1%on this news
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
Pasithea Therapeutics announced the initiation of a Phase 1/1b clinical study for PAS-004, targeting adult patients with neurofibromatosis type 1 (NF1). The trial will assess safety, tolerability, and preliminary efficacy of the drug, with the first patient expected to be dosed in Q2 2025. The study will be conducted at multiple sites including the first site in Australia, with additional locations planned in South Korea and the U.S. The company is optimistic about the trial's potential, bolstered by R&D tax incentives to support costs.
Read more →KTTA▼ -25.7%on this news· ran to -43% by day 3
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
Pasithea Therapeutics announced the closing of a public offering that raised $5 million, selling 3,571,428 shares of common stock priced at $1.40 each. The company will use the net proceeds for various corporate purposes including ongoing research and clinical trials. Additionally, certain investors exercised Series D warrants, bringing gross proceeds to approximately $6.3 million. The event underscores the company's funding strategy as it advances its clinical-stage projects targeting neurofibromatosis type 1 and other indications.
Read more →KTTA▲ +7%on this newsshared move
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering Miami, FL / GLOBE NEWSWIRE /
Pasithea Therapeutics has announced a public offering of 3,571,428 shares priced at $1.40 each, aiming to raise approximately $5 million. The company plans to utilize the proceeds for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions. The offering is expected to close on or around May 7, 2025, subject to customary conditions. H.C. Wainwright & Co. serves as the exclusive placement agent for this transaction.
Read more →KTTA▲ +7%on this newsshared move
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
Pasithea Therapeutics has reported positive interim pharmacodynamic results from its ongoing Phase 1 clinical trial of PAS-004, a MEK inhibitor targeting advanced cancer. The study demonstrated up to 91% inhibition of pERK levels, validating substantial target engagement. Notably, one patient with stage 4 KRAS G12R-mutated pancreatic cancer achieved over 5 months of stable disease with a tumor volume reduction of 9.8%. The trial's findings indicate encouraging clinical activity, with the company planning to share more comprehensive data in the future.
Read more →KTTAPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients
Pasithea Therapeutics announced the successful completion of enrollment and initial dosing of three patients in Cohort 6 of its Phase 1 trial for PAS-004, a macrocyclic MEK inhibitor aimed at treating advanced cancer. The trial specifically focuses on patients with mutations in the MAPK pathway, including RAS or NF1. CEO Dr. Tiago Reis Marques highlighted the rapid recruitment and dosing progress, with plans to complete overall trial enrollment by the end of 2025.
Read more →KTTA▲ +5.5%on this newsshared move
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting
Pasithea Therapeutics Corp. has announced the acceptance of an abstract for a presentation at the 2025 ASCO Annual Meeting, where they will provide updated interim data from their ongoing Phase 1 trial of PAS-004. The trial focuses on patients with MAPK pathway driven advanced solid tumors. Interim results highlight the clinical activity, safety profile, and pharmacokinetic properties of PAS-004, suggesting its potential as a treatment option for neurofibromatosis type 1 and other malignancies. The presentation will occur on June 2, 2025, during the developmental therapeutics session.
Read more →KTTA▲ +46.8%on this news
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea Therapeutics announced that the external Safety Review Committee has recommended escalating the dose of PAS-004 in its Phase 1 clinical trial for advanced cancer to 30mg capsules. The decision comes after a review of safety data from earlier cohorts, which demonstrated no dose-limiting toxicities or rash, common side effects associated with competitor MEK inhibitors. The trial aims to evaluate PAS-004's safety and efficacy among patients with MAPK pathway-driven tumors. The company is also witnessing substantial enrollment interest for the next cohort.
Read more →KTTAPasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
Pasithea Therapeutics Corp. (NASDAQ: KTTA) will present at the 2025 CAGLA NeauxCancer Conference in New Orleans from March 27-29, 2025. The company's Vice President of Business Development, Mathew Lazarus, will discuss the ongoing Phase 1 study results of PAS-004, a macrocyclic MEK inhibitor for neurofibromatosis type 1 and other cancer indications. The conference is a significant global forum in oncology, focusing on groundbreaking advancements in cancer treatment.
Read more →KTTA▲ +31.7%on this news
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea Therapeutics Corp. announced a positive recommendation from the Safety Review Committee for its Phase 1 clinical trial of PAS-004 in advanced cancer, allowing the trial to proceed to the next dose level of 22mg. The recommendation came after reviewing safety data indicating no adverse events, including dose-limiting toxicities or rash, in the participants thus far. Chief Executive Officer Dr. Tiago Reis Marques expressed optimism regarding the safety profile and potential implications of PAS-004 for treating neurofibromatosis type 1 and other cancers, with further pharmacokinetic and pharmacodynamic data expected to be presented in Q1 2025.
Read more →KTTAPasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
Pasithea Therapeutics Corp. has opened three clinical trial sites in Romania and Bulgaria as part of its Phase 1 trial for the cancer treatment PAS-004. The company has completed initial dosing for Cohort 4A, which involves 15mg capsules, while recruitment for Cohort 4B continues with 4mg tablets. Interim safety and pharmacokinetic data from both cohorts are expected to be presented in Q1 2025. This development is aimed at evaluating the treatment in patients with specific tumor types that are more responsive to MEK inhibitors.
Read more →KTTA▲ +52.1%on this news
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules MIAMI, FL.
Pasithea Therapeutics has announced a $5 million private placement priced at-the-market. This transaction involves the issuance of 1,219,513 shares of common stock along with accompanying warrants. The proceeds are intended for working capital and corporate purposes. The private placement is managed by H.C. Wainwright & Co. and is expected to close around September 30, 2024, pending customary conditions.
Read more →KTTA▲ +52.1%on this news
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer -- Single patient in 2mg cohort wit
Pasithea Therapeutics announced positive initial results from its Phase 1 clinical trial of PAS-004, a next-generation MEK inhibitor for advanced cancer. The data indicate no treatment-related adverse events and a patient with stage 3 colon cancer showed prolonged stable disease. With a pharmacokinetic profile suggesting a half-life of approximately 70 hours, PAS-004 may allow for once-daily dosing, distinguishing it from first-generation MEK inhibitors. The company is proceeding to the next dosing cohort and plans to continue providing updates on the trial's progress.
Read more →KTTAPasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
Pasithea Therapeutics Corp. announced the successful completion of chronic toxicity studies for its drug PAS-004, designed to treat neurofibromatosis type 1 and other cancers. The studies showed a consistent safety profile in both rats and dogs, affirming previous short-term findings. Notably, a no adverse effect level was established in dogs, supporting PAS-004's potential as a leading MEK inhibitor. The company anticipates sharing additional data from its Phase 1 clinical trial soon.
Read more →KTTA▲ +6.6%on this news
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
Pasithea Therapeutics has appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, a recognized expert in neurofibromatosis type 1 (NF1), will provide valuable insights as Pasithea advances its development of PAS-004, a macrocyclic MEK inhibitor. The drug aims to address unmet needs in NF1 treatment and boasts several advantages over existing therapies. The company is preparing to initiate a Phase 1/2a clinical trial for PAS-004, which has received orphan-drug designation from the FDA.
Read more →KTTAPasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, where management will present the company's developments, including its next-generation MEK inhibitor for Neurofibromatosis type 1. The online presentation will commence at 7:00 a.m. ET on September 9th, with additional one-on-one meetings scheduled in New York City until September 11th. Pasithea focuses on innovative treatments for CNS disorders and RASopathies, with a dedicated team in drug development.
Read more →KTTAPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Pasithea Therapeutics has announced the completion of enrollment and initial dosing for the second cohort in its Phase 1 clinical trial of PAS-004, a macrocyclic MEK inhibitor. The trial was recommended to escalate dosage after a positive review from an independent Safety Review Committee, which found no concerning adverse events in the first cohort. The company aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of PAS-004 in treating patients with specific advanced solid tumors and neurofibromatosis type 1. Initial safety and pharmacokinetic data are expected in the third quarter of 2024.
Read more →KTTAPasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Pasithea Therapeutics has announced compelling preclinical data for PAS-004, demonstrating its effectiveness in inhibiting NRAS mutant cancer cell lines and superior activity in xenograft studies compared to existing approved MEK inhibitors. The findings, set to be presented at the 2024 ASCO Annual Meeting, suggest that PAS-004 may offer enhanced potency, with fewer side effects and improved dosing schedules. This positions PAS-004 as a promising candidate for the treatment of neurofibromatosis type 1 and various cancers, marking it as a pioneer in macrocyclic MEK inhibitors as it prepares for clinical trials.
Read more →KTTAPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Pasithea Therapeutics announced that an abstract related to their drug PAS-004 has been accepted for a poster presentation at the upcoming 2024 ASCO Annual Meeting. PAS-004, a next-generation macrocyclic MEK inhibitor, is being developed for neurofibromatosis type 1 and other indications. The acceptance to present signifies recognition of their research, which aims to improve treatment efficacy and safety profiles compared to existing MEK inhibitors. The poster presentation is scheduled for June 1, 2024, in Chicago.
Read more →KTTAPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Pasithea Therapeutics has announced the completion of initial dosing for the first cohort of three patients in a Phase 1 trial evaluating PAS-004 for RAS, NF1, and RAF mutated cancers. This trial represents a significant milestone for the development of PAS-004 as a next-generation MEK inhibitor, which aims to provide improved safety and efficacy over existing therapies. The company plans to expand its clinical evaluation, including potential trials for NF1 patients with specific tumor types, enhancing its development program. PAS-004 has already received orphan-drug designation from the FDA, highlighting its potential therapeutic significance.
Read more →KTTA▲ +9%on this news· ran to +22% by day 3
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Pasithea Therapeutics Corp. has announced the activation of four clinical trial sites in the United States for its Phase 1 trial of PAS-004, aimed at treating neurofibromatosis type 1 and advanced solid tumors. The trial has received FDA approval, allowing enrollment at sites in Texas and Virginia, with plans to open additional sites in Eastern Europe. The study will assess the safety and preliminary efficacy of PAS-004, with interim results expected in the second half of 2024. The company believes PAS-004 could become a next-generation MEK inhibitor with better safety and efficacy profiles.
Read more →KTTA▲ +5%on this news
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Pasithea Therapeutics has announced the invention of a crystalline form of its drug PAS-004, supported by new polymorph and stereoisomer patent filings, extending patent protection to at least 2045. This development is expected to enhance the value of PAS-004, an allosteric inhibitor of MEK 1/2, which has demonstrated positive preclinical results. The upcoming phase 1 trial will utilize this newly invented drug substance, further indicating progress in its development pipeline. The innovation aligns with the company's focus on CNS disorders and RASopathies, marking a significant milestone in their research endeavors.
Read more →KTTA▲ +8.8%on this news
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea Therapeutics announced that the FDA has accepted its IND application for PAS-004, the first macrocyclic MEK inhibitor to enter human clinical trials. This Phase 1 dose escalation study will evaluate PAS-004 in patients with advanced solid tumors driven by the MAPK pathway, with initial readouts expected by Q3 2024. The company views this acceptance as a significant milestone, aiming to establish PAS-004 as a potentially best-in-class treatment option. The clinical trial is anticipated to begin in Q1 2024, marking Pasithea's advancement into the clinical stage of development.
Read more →KTTAPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Pasithea Therapeutics Corp. has announced the adjournment of its stockholders' meeting, initially held on December 19, 2023, to December 29, 2023. During this period, the company aims to gather additional votes regarding specific charter amendment proposals outlined in their recent proxy statement. The board of directors is advocating for the approval of these proposals, which they believe are beneficial for shareholders. Voting remains open solely for these adjourned proposals, while other proposals have already been approved.
Read more →KTTA▼ -6.1%on this news· ran to -19% by day 1
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
Pasithea Therapeutics Corp. held its annual meeting of stockholders on December 19, 2023, where over 70% of shares were represented. The company announced that more than 95% of votes were approved for the election of directors and other key proposals. An adjourned meeting has been scheduled for December 28, 2023, to address additional charter amendment proposals requiring further votes. The company encourages stockholders who have not yet voted on these proposals to do so promptly.
Read more →KTTA▲ +47.4%on this news
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics announced positive preclinical results for PAS-004, demonstrating significant anti-tumor efficacy in NRAS mutation cancer xenograft models. In two studies, PAS-004 exhibited superior effects compared to FDA-approved MEK inhibitors like binimetinib and selumetinib. These findings support the upcoming Phase 1 clinical trial expected to commence in early 2024, which will assess PAS-004 in patients with specific advanced solid tumors. The company believes the drug's macrocyclic structure could enhance its pharmacokinetics and safety profile.
Read more →KTTA▲ +6.6%on this news
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Pasithea Therapeutics Corp. has announced the adjournment of its 2023 Annual Meeting of Stockholders, originally held on November 29, 2023. The meeting was adjourned to allow stockholders more time to vote on proposals outlined in the Proxy Statement filed with the SEC. The meeting is set to reconvene on December 19, 2023, at which all proposals will be voted upon. The Company encourages stockholders who haven't voted yet to do so before the reconvened meeting.
Read more →KTTA▲ +6.6%on this news
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Pasithea Therapeutics announced the outcome of a Pre-IND meeting with the FDA regarding PAS-004, which is set to begin a Phase 1 trial in early 2024. The FDA's positive feedback encourages dosing in patients with specific genetic mutations rather than healthy volunteers. PAS-004 is designed to be an allosteric inhibitor of MEK 1/2, potentially offering better safety and efficacy profiles compared to existing MEK inhibitors. The company aims to submit the IND application by the end of Q4 2023.
Read more →KTTAPasithea Therapeutics Corp. Announces Final Results of Tender Offer -- Purchases All 5,323,451 Shares Validly Tendered at $0.70 per Share -- PALO ALTO, Calif. and
Pasithea Therapeutics Corp. announced the results of its tender offer, acquiring 5,323,451 shares at $0.70 per share. The offer expired on September 8, 2023, and no proration occurred as all valid tenders were accepted. CEO Dr. Tiago Reis Marques noted the buyback reflects stockholder confidence and provides liquidity options, while also preserving cash for the company's ongoing development projects, including new drug candidates for CNS disorders. Following the offer, 20,819,956 shares will remain outstanding.
Read more →KTTAPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Pasithea Therapeutics Corp. has announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference taking place from September 11-13 in New York City. The conference provides a platform for attendees to request one-on-one meetings with the company's management. Pasithea focuses on developing treatments for CNS disorders and RASopathies, including conditions like NF1, ALS, and MS. The announcement highlights the company's commitment to engaging with investors and discussing its research and development efforts.
Read more →KTTA▲ +25.9%on this news
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash -- Tender Offer Expected to Close Third Quarter of 2023 -- PALO ALTO, Calif. and
Pasithea Therapeutics Corp. has announced an intention to initiate a $4.0 million tender offer for its common stock at a price of $0.70 per share. The company plans to repurchase approximately 5.7 million shares, pending shareholder participation. The tender offer is expected to close in the third quarter of 2023, although it has not yet commenced, and there are no guarantees regarding its completion or participation from management. Shareholders will be provided detailed instructions following the offer's commencement.
Read more →KTTA▲ +25.9%on this news
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
Pasithea Therapeutics Corp. has confirmed the rejection of an unsolicited acquisition proposal from Lucy Scientific Discovery, Inc. The Special Committee of Pasithea's Board of Directors conducted a thorough review of the bid, which involved cash and stock components, and deemed it not in the company's best interests. The committee asserted that the proposal did not adequately reflect Pasithea's strategic value or future growth prospects. The company remains focused on developing treatments for CNS disorders and RASopathies.
Read more →KTTAPasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
Pasithea Therapeutics Corp. has reaffirmed the establishment of a Special Committee within its Board of Directors, tasked with evaluating an unsolicited acquisition proposal from Lucy Scientific Discovery Inc. The proposal includes cash and stock options for shareholders. The Special Committee is consulting with financial and legal advisors to assess the offer while ensuring the best interests of all shareholders are served. Currently, no action is required from Pasithea shareholders.
Read more →KTTA▲ +11.2%on this newsshared move
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
Pasithea Therapeutics announced the successful completion of GMP-compliant manufacturing for PAS-004, its lead product candidate. This milestone supports the upcoming Investigational New Drug (IND) application expected to be filed with the FDA within 2023. The company plans to initiate a Phase 1 clinical trial by the end of the year, focusing on the drug's potential for once-a-day dosing. Additionally, PAS-004 has received orphan-drug designation for the treatment of Neurofibromatosis type 1.
Read more →KTTAPasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
Pasithea Therapeutics Corp. has confirmed receipt of an unsolicited acquisition proposal from Lucy Scientific Discovery Inc., offering $0.60 in cash along with $0.25 in Lucy stock for each share of Pasithea. The Board of Directors is reviewing the proposal with independent advisors to ensure decisions are aligned with shareholder interests. Shareholders are currently advised not to take any action as the situation develops. The proposal reflects interest in Pasithea's innovative treatments for CNS disorders.
Read more →KTTAPasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
Pasithea Therapeutics announced the acceptance of its pre-clinical results for PAS-004 at the 2023 Neurofibromatosis Conference. This presentation will showcase insights into PAS-004's efficacy derived from research conducted in collaboration with Indiana University. PAS-004, an innovative MEK inhibitor, may offer advantages over existing treatments, including improved pharmacokinetics and safety profiles. The conference serves as a vital platform for advancing neurofibromatosis research and fostering collaborations within the scientific community.
Read more →KTTAPasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
Pasithea Therapeutics Corp. announced that its CEO and VP of Business Development will participate in the EF Hutton Global Conference in New York City on May 10-11, 2023. The event aims to foster interactions between executives and investors from a variety of sectors, including healthcare and life sciences. It will feature one-on-one meetings designed to create a dynamic networking environment. The company specializes in developing treatments for various central nervous system disorders, including ALS and MS.
Read more →KTTAPasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
Pasithea Therapeutics Corp. has announced that Prof. Lawrence Steinman, the company’s Chairman, will deliver a keynote address at the upcoming AAAS Annual Meeting in Washington DC. This event is significant as it is one of the largest scientific gatherings, and Steinman's research has been acknowledged for its contributions to understanding Multiple Sclerosis. His work is particularly focused on the Epstein-Barr virus's connection to MS, bringing greater awareness to this autoimmune disease. The company is also advancing its PAS-002 program, which aims to develop a novel vaccine targeting the underlying mechanisms of MS.
Read more →KTTA▼ -5.6%on this news
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Pasithea Therapeutics Corp. announced that its Chairman, Prof. Lawrence Steinman, will deliver the Dr. Kenneth P. Johnson lecture at the ACTRIMS in San Diego. The lecture emphasizes significant scientific advancements in multiple sclerosis (MS) treatment and research. Steinman's notable research on the relationship between Epstein-Barr virus and MS was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year. Pasithea's ongoing PAS-002 discovery program aims to develop a novel DNA plasmid vaccine targeting GlialCAM for MS treatment.
Read more →KTTAPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award
Pasithea Therapeutics announced that its Chairman, Prof. Lawrence Steinman, will receive the 2023 Pioneer in Medicine Award for his significant contributions to brain mapping and therapeutics. The award, presented during the 20th Annual Gathering for the Cure, recognizes his work on the molecular mimicry related to Multiple Sclerosis. Prof. Steinman emphasized the importance of innovating treatments for this debilitating disease. The company’s PAS-002 program focuses on creating a DNA plasmid vaccine to target a critical CNS protein involved in MS.
Read more →KTTAPasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004
Pasithea Therapeutics has entered a manufacturing agreement with WuXi STA for the production of PAS-004, a mekinhibitor aimed at treating neurofibromatosis type 1. Following successful pre-clinical testing and toxicology studies, Pasithea plans to file an Investigational New Drug application with the FDA by mid-2023. The company is optimistic about its upcoming Phase 1 clinical trial, citing the advantages of PAS-004's macrocyclic structure over traditional MEK inhibitors. Pasithea's focus is on innovative CNS disorder treatments.
Read more →KTTA▼ -8.2%on this news· ran to -19% by day 3
Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group
Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research an
Read more →KTTAPasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
MIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disorders, today ann
Read more →KTTAPasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time
MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“CNS”) disorders, today a
Read more →KTTA▼ -11.2%on this news
Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium
MIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced
Read more →KTTAPasithea Therapeutics Acquires AlloMek Therapeutics -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Cl
Pasithea Therapeutics Acquires AlloMek Therapeutics -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinica
Read more →KTTAPasithea Therapeutics to Call Special Meeting of Stockholders
MIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders, to
Read more →KTTAPasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (“CNS”) disorders,
Read more →KTTAPasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases -- MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotec
Read more →KTTAPasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announce
Read more →KTTAPasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
-- Annual “From Laboratory to Clinic” conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine -- -- PAS002 is a proprietary DNA vaccine construct encoding GlialCAM -- MIAMI BEACH, Fla., Aug. 18, 2022 (GLOBE NEWSWI
Read more →KTTA▲ +6.8%on this news
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM -- -- PAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity -- -- GlialCAM fragment is present in monkeypox virus, supporting a potential role in c
Read more →KTTAPasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign
Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash Grab Board Unanimously Recommends Stockholders to Sign, Date and Return GOLD Consent Revocation Card MIAMI BEACH, Fla., Au
Read more →KTTA▲ +5%on this news
Pasithea Therapeutics Awarded a Drug Development Research Grant
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding -- MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therape
Read more →KTTAPasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond
MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today ann
Read more →KTTAPasithea Therapeutics Acquires Alpha-5 Integrin, LLC - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological dis
Pasithea Therapeutics Acquires Alpha-5 Integrin, - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases - - Expands pipeline across Pasithea's core therapeutic areas to drive enhan
Read more →KTTAPasithea Therapeutics Acquires Alpha-5 Integrin, LLC
- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases - - Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth - - Closing consideration of 3.26 millio
Read more →KTTA▲ +9.8%on this news
Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today an
Read more →KTTAPasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022
-- Cash Balance of $52.9 million to fund operations well into 2024 -- -- Initiation of a drug development program in schizophrenia -- -- Initiation of a drug development program in multiple sclerosis -- -- Launched ketamine clinics in the U.K. and U.S. and expanded treatment o
Read more →KTTA▲ +7.1%on this news
Pasithea Therapeutics Announces Collaboration with The Glimpse Group
- The Glimpse Group is a Virtual Reality and Augmented Reality platform company - Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders MIAMI BEACH, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTT
Read more →KTTAPasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimulation (“rTMS”) -- MIAM
Read more →KTTAPasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger
MIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today ann
Read more →KTTA▼ -6.4%on this news
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis
MIAMI BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced
Read more →KTTAPasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments
MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today ann
Read more →KTTA▲ +9.7%on this news· ran to +28% by day 3
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
MIAMI BEACH, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today ann
Read more →KTTA▼ -8.6%on this news· ran to -24% by day 3
Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada
-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals -- -- Expansion to additional U.S. cities in coming months -- MIAMI BEACH, Fla., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Pasit
Read more →KTTA▲ +6%on this news· ran to -16% by day 3shared move
Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today an
Read more →KTTA▼ -28.7%on this newsshared move
Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced At a Premium to the Market Under Nasdaq Rules Miami Beach, FL
Therapeutics Corp. Announces Pricing of a $30.4 Million Placement Priced At a Premium to the Market Under Nasdaq Rules Miami Beach, FL, November 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) ("Pasithea" or the "Company"), a biotechnology compan
Read more →KTTA▲ +153.4%on this newsshared move
Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
MIAMI BEACH, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today ann
Read more →KTTA▼ -5.2%on this news
Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
-- Pasithea Clinics to offer ketamine infusion therapy for the treatment of mental health disorders -- -- First mobile clinics launch in New York City, Los Angeles, San Diego, and San Francisco, with expansion to additional U.S. cities in coming months -- -- Treatments conducte
Read more →KTTAPasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy
MIAMI BEACH, Fla., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announc
Read more →KTTAPasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair
MIAMI BEACH, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced
Read more →KTTA▲ +9.2%on this news
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
MIAMI BEACH, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today ann
Read more →KTTA▲ +8.2%on this news
Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom
-- Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders -- -- Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric
Read more →KTTAPasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement
MIAMI BEACH, Fla., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced
Read more →KTTAPasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference
MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announce
Read more →KTTA▼ -6%on this news· ran to -18% by day 3
Pasithea Therapeutics Corp. Announces Closing of $24.0 Million Initial Public Offering
MIAMI BEACH, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announce
Read more →KTTAPasithea Therapeutics Corp. Announces Pricing of Upsized $24.0 Million Initial Public Offering
MIAMI BEACH, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company"), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the pricing o
Read more →Competitive Position
How KTTA ranks across every disease it competes inCompetitive Position is a premium feature
See how KTTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial